The vision correction field has never advanced faster than it is advancing now. In the span of three decades, the field moved from rudimentary radial keratotomy (manual corneal incisions) to femtosecond laser tissue extraction guided by artificial intelligence. The pace of innovation is accelerating, not slowing.
This guide reviews the technologies currently in advanced clinical use, those in active trials approaching adoption, and the more speculative but scientifically grounded directions that will define vision correction over the next decade. It is part of the Vision Correction Procedures Compared hub.
Where We Are Now: The 2026 Baseline
To understand where the field is going, it helps to be clear about where it stands. Current best practices in refractive surgery include:
- Wavefront-guided and topography-guided laser ablation: Personalized ablation profiles that address not just the primary refractive error but the eye’s unique higher-order aberrations.
- SMILE with VISUMAX 800: Flapless femtosecond lenticule extraction with refined astigmatism correction and improved alignment technology.
- EVO ICL with central port: The latest generation of Implantable Collamer Lens eliminates the need for peripheral iridotomies, streamlining the procedure.
- Trifocal and EDOF IOLs: Premium intraocular lenses that deliver functional vision at multiple distances for RLE and cataract patients.
- Light-Adjustable Lens (LAL): Post-implantation UV refinement of IOL power for precision not achievable with fixed-optic lenses.
- AI-assisted biometry and IOL calculation: Machine learning models that integrate multiple biometric inputs to predict IOL power with greater accuracy than traditional formulas.
This is the current state of the art. Everything below represents what is emerging or coming next.
Near-Term: Technologies Approaching or Entering Clinical Adoption
AI-Guided Laser Treatment Planning
Artificial intelligence is transforming the planning phase of refractive surgery. The traditional approach to LASIK or PRK treatment planning uses nomogram adjustments — surgeon-specific corrections applied to the laser’s nominal calculation based on accumulated experience. AI replaces this with a predictive model trained on thousands of previously treated cases.
Early publications from AI-guided laser nomograms show a meaningful reduction in residual refractive error at one month postoperatively. Rather than 90–92% of patients within 0.50D of emmetropia (the typical range for conventional planning), AI-guided planning in several published series has achieved 95–98% within 0.50D.
The practical implication: fewer enhancements, better first-surgery outcomes, and improved patient satisfaction. As more practices adopt AI planning tools, this will become the new standard of care rather than a premium add-on.
VISUMAX 800 and Expanded SMILE Indications
The VISUMAX 800 platform has enabled faster lenticule extraction with improved astigmatism precision. Clinical trials are ongoing for extended SMILE parameters — specifically:
- Higher myopia: up to -12.00D in some investigational protocols
- Higher astigmatism: expansion beyond -3.00D through improved axis registration
- SMILE for hyperopia: investigational in Asia, with early data showing feasibility, though precision challenges remain
If hyperopic SMILE achieves FDA approval in the US, it would be a significant expansion of SMILE’s applicability — currently its most significant limitation.
Extended-Range EVO ICL Designs
The current EVO ICL is a single-focus lens — excellent for correcting myopia and astigmatism but unable to address presbyopia. The next generation of ICL development involves:
- Trifocal ICL: Incorporating diffractive presbyopia-correcting optics into the ICL design for patients who want both high myopia correction and near vision without glasses.
- EDOF ICL: Extended depth of focus optics built into the phakic IOL — providing an extended visual range without removing the natural lens.
These designs are in clinical evaluation in multiple markets. The technical challenge is significant: a phakic IOL that also corrects presbyopia would represent a paradigm shift in the treatment of high myopia with presbyopia — currently a particularly underserved population.
Topography-Guided Treatment Evolution
Topography-guided laser treatment (Contoura Vision in the US, AMARIS platforms internationally) uses detailed corneal surface mapping to produce individualized ablation profiles that address corneal irregularities not captured by standard wavefront analysis. Current evidence shows that topography-guided LASIK produces superior optical quality metrics and lower higher-order aberration induction compared to wavefront-optimized LASIK for many patients.
The next step is combining topography guidance with real-time intraoperative mapping — tracking corneal shape during the ablation itself and adjusting the laser in real time to account for hydration changes and flap effects. This is a meaningful remaining source of outcome variability that real-time adaptive tracking would address.
Medium-Term: In Active Development
PiXL — Photorefractive Intrastromal Crosslinking
PiXL (Photorefractive Intrastromal Crosslinking) is an entirely new approach to non-laser refractive correction. Instead of ablating corneal tissue, PiXL uses UV light to selectively stiffen (crosslink) zones of the corneal stroma, changing its curvature through differential biomechanical stiffening rather than tissue removal.
Potential advantages:
- No tissue removal means no ectasia risk — the cornea is strengthened, not weakened
- Reversibility may be possible through targeted relaxation techniques
- Could enable treatment of patients currently excluded from laser surgery due to thin corneas
PiXL is in clinical trials at multiple sites globally. Early human data show measurable refractive correction, though precision and repeatability are still being established. A commercially viable PiXL system remains several years from US approval, but the underlying science is sound and the clinical appeal is substantial.
Gene Therapy for Myopia Progression
The global myopia epidemic — affecting 2.6 billion people and projected to affect nearly half the global population by 2050 — has attracted research into genetic and biological interventions to halt axial elongation before it reaches levels requiring surgery.
Current approaches under investigation include:
- Anti-VEGF-based treatments targeting the retinal signal cascade that drives scleral remodeling in myopia
- Atropine gene therapy — sustained low-dose atropine delivery via viral vector to ciliary body tissue
- CRISPR-based approaches targeting genes associated with high myopia susceptibility, currently only in preclinical models
None of these are near clinical adoption, but they represent the potential future of myopia management — preventing the refractive error rather than correcting it after it develops.
Presbyopia Pharmacological Treatment
Several companies are developing pharmacological approaches to presbyopia — eye drops that temporarily restore near focus by changing the mechanical properties of the crystalline lens or by inducing pupil constriction.
Vuity (pilocarpine 1.25%) — FDA-approved in 2021, this drop uses mild pupillary constriction to increase depth of focus and improve near vision for 6–8 hours. It is the first pharmacological presbyopia treatment approved in the US. Limitations include variable efficacy, headache in some users, and duration.
Next-generation drops targeting lens stiffness directly (rather than pupil constriction) are in Phase II and III trials. If successful, these could provide reversible, medication-based presbyopia correction — the first fundamentally new approach to this ubiquitous condition.
Longer-Term: Speculative but Scientifically Grounded
Accommodating IOLs
The vision correction industry has pursued the truly accommodating IOL — one that moves or changes shape in response to ciliary muscle contraction, restoring real dynamic near focus after RLE or cataract surgery — for decades without fully achieving it. Current “accommodating” IOLs (e.g., Crystalens) show limited amplitude of true accommodation.
Next-generation designs using fluid-based lenses, shape-memory polymers, and nanotechnology-enabled optics are advancing in research. A truly accommodating IOL would fundamentally change the RLE landscape.
Digital Light Delivery in Surgery
Real-time feedback systems that measure the refractive outcome of each laser pulse during LASIK or PRK and adjust subsequent pulses accordingly — essentially a closed-loop laser system — are in early-stage development. Current systems plan the treatment before surgery and execute it open-loop. Closed-loop correction would address the remaining variability from intraoperative hydration changes and stromal response.
Related Resources
- SMILE Eye Surgery: What You Need to Know
- Refractive Lens Exchange: Vision Correction for Older Adults
- Vision Correction Procedures Compared
- What Are the Newest Vision Correction Technologies?
- How Has Vision Correction Surgery Improved in Recent Years?
- What Is the Best Vision Correction Surgery?
*This content is educational and does not constitute medical advice. Technologies described as “in development” or “investigational” are not yet commercially available in all markets. Consult a qualified ophthalmologist regarding available options.*